---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-093721"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2026-08-11T11:09:16+00:00"
generated_at: "2026-08-11T11:10:07.360226+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CVRx CRO Robert John departs; Paul Verrastro named interim head of sales

## Summary
- Robert John terminated as CRO effective Aug 10, 2026; eligible for severance under employment agreement.
- Paul Verrastro named Interim Head of Sales, effective immediately; leads search for permanent successor.
- Verrastro has 30+ years med-device sales experience; former CMO at CVRx, previously Guidant, Boston Scientific, Medtronic.
- CEO Kevin Hykes cites revised commercial outlook and need to improve commercial execution for the change.

## SEC filing metadata
- accession: 0001104659-26-093721
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2026-08-11T11:09:16+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465926093721/0001104659-26-093721-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465926093721/tm2622791d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-093721
- JSON: https://secwatch.observer/filing/0001104659-26-093721.json
- Plain text: https://secwatch.observer/filing/0001104659-26-093721.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.